A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Trial Profile

A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Glycopyrrolate (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 31 May 2017 Status changed from active, no longer recruiting to completed.
    • 24 May 2017 Primary endpoint (Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 for all Glycopyrrolate (GP) MDI doses versus Placebo) has been met, according to results presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top